The Filing Desk

MiMedx Group

MDXG · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MDXG · Last close · November 19, 2026
$3.11
Value MiMedx Group yourself

MiMedx Group's revenue rose 20.0% to $419 million in fiscal 2025. Its operating margin was 15.3%, down from 16.9% a year earlier. The diluted share count rose 0.5%.

MIMEDX GROUP, INC. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001376339-26-000011 Updated
Revenue
$419M
20.0%
Operating margin
15.3%
1.6 pts
Net income
$49M
14.5%
Free cash flow
—
 
Return on capital
43.3%
3.8 pts
Market cap
$454M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What MiMedx Group does

MiMedx sells products that help heal chronic and hard-to-heal wounds, and it also serves burn care and surgery. Clinicians typically use them when a patient is slow to respond, or doesn't respond, to conventional treatment.

Historically its products were made from placental tissue, which is human birth tissue donated by mothers and processed into products that can treat many people. In 2024 it added animal-derived products, called xenografts. In 2025 and early 2026 it signed agreements with makers of other wound care products to widen what it offers. It says it gets tissue through a donor network of hospitals and clinician groups that it built over more than a decade.

Its revenue depends on insurers and health systems reimbursing the cost of its products. It competes with established tissue processors and medical device makers.

Its biggest risks, as it describes them

  • Many of its products depend on tissue from human donors, so a supply disruption would hurt it.
  • Its revenue depends on insurers and health systems paying for its products, and reimbursement rules can change.
  • Competition from established tissue processors and device makers, and rapid technology change.
  • It depends on its senior leaders, and changes in leadership can disrupt the business.
From MiMedx Group's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2025, earnings per share fell 6.8% a year and net income 3.5% a year, as new shares raised the share count by 29% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments876682104166
Debt incl. finance leases5050501918
Net debt (negative means net cash)−37−16−32−85−148
Net debt to EBITDA——−0.8x−1.3x−1.9x
Debt to equity——0.3x0.1x0.1x
Interest coverage−1.6x−2.9x5.7x14.9x35.8x
Current ratio3.5x3.1x3.6x4.2x4.3x
Quick ratio3.2x2.8x3.1x3.7x3.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project MiMedx Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of MiMedx Group reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 95 of 97 of 9
Rule of 4027.7%——
Altman Z''4.026.878.06
Accruals ratio15.3%−9.5%−8.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassFailPass
F-score7 of 95 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put MiMedx Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MiMedx GroupFY2520.0%15.3%—43.3%−1.9x7
AccurayFY26−12.3%−6.6%−3.2%———Compare
ArtivionFY2513.6%7.7%0.2%3.9%2.7x7Compare
InModeFY25−6.2%23.1%22.8%———Compare
InogenFY253.9%−8.7%−3.9%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue222321359299248242268322349419
Revenue growth18.4%44.9%11.8%−16.7%−17.1%−2.5%10.7%20.0%8.5%20.0%
Gross profit191286323256209202220267289346
Research and development14181611121013131215
Operating income146−4−21−45−7−15375964
Net income065−30−26−49−10−30584249
Diluted EPS (US$)0.000.56−0.28−0.24−0.77−0.15−0.330.370.280.32
Diluted shares (millions)113116106107108110113146149150
Cash flow
Cash from operations246336−39−30−2−18276674
Capital expenditure—————322——
Free cash flow—————−5−1925——
Dividends paid0000000000
Share buybacks1068801001000
Acquisitions8000000084
Stock-based compensation18211512151411171716
Balance sheet at fiscal year end
Cash and short-term investments3028456996876682104166
Debt incl. finance leases——073505050501918
Total assets117121123167202188171239264343
Total liabilities6948731331119597967186
Shareholders' equity48745034−00−18143193256
Margins and ratios
Gross margin86.0%89.0%89.9%85.6%84.2%83.6%82.0%83.0%82.8%82.6%
Operating margin0.4%14.4%−1.1%−7.1%−18.3%−2.9%−5.5%11.6%16.9%15.3%
Net margin0.2%20.2%−8.3%−8.6%−19.9%−4.2%−11.3%18.1%12.2%11.6%
Free cash flow margin—————−2.1%−7.2%7.7%——
Rule of 40 (growth + FCF margin)—————−4.7%3.4%27.7%——
Return on capital———−77.8%———96.5%39.5%43.3%
Return on equity0.9%106.2%−48.6%−60.9%−287.8%——93.4%25.3%21.6%
Return on assets0.3%54.3%−24.6%−17.6%−26.7%−5.3%−16.8%28.4%16.9%16.0%
Net debt to EBITDA——−15.1x————−0.8x−1.3x−1.9x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: MiMedx Group's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with MiMedx Group.